Phase 2 Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 21 years or older.
- People with a confirmed diagnosis of HER2-positive cancer, based on laboratory testing of tumour tissue (specific testing methods are used to confirm HER2 status).
- For the first phase of the trial: people with HER2-positive breast cancer, stomach (gastric) cancer, or other HER2-positive solid tumours that have not responded to previous treatments.
- For the second phase of the trial: people with HER2-positive breast cancer.
- People with a good general level of physical function, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities).
- People whose cancer can be measured or assessed using standard imaging criteria.
- People with an estimated life expectancy of at least 12 weeks.
- People with HER2-positive breast cancer who have already tried and not responded to at least two prior HER2-targeted treatments for advanced or metastatic disease (relapsing within 6 months of completing an earlier HER2-targeted treatment course counts as one prior line).
- People with HER2-positive stomach cancer who have already tried and not responded to at least one HER2-targeted treatment.
- People with other HER2-positive solid tumours (not breast or stomach) where no standard treatments are available, or who have already tried standard treatments without success or were unable to tolerate them.
- People who have recovered from side effects caused by previous cancer treatments.
- People whose heart is pumping at 50% or more of its normal capacity, based on a heart scan.
- People with adequate bone marrow, liver, and kidney function, confirmed through blood tests (confirm with trial site for specific values required).
- People willing and able to give signed informed consent, either personally or through a legal representative.
- People who are able to follow the study procedures and attend required visits.
- For specific groups within the trial (cohorts 3, 4, and 5): people with a past history of blood clots in the veins may be considered eligible, as long as they are currently receiving appropriate blood-thinning medication.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have taken part in another clinical trial and received an experimental drug within the last 30 days.
- People currently receiving any other cancer treatment, including chemotherapy, hormone therapy, or immunotherapy.
- People who have had major surgery within 28 days before starting the study drug.
- People with an active infection that the study doctor believes would make it unsafe to receive the treatment.
- People who are pregnant.
- People who are breastfeeding.
- People with serious other health conditions that the study doctor believes could put them at risk or prevent them from completing the study.
- People with an active bleeding disorder or an active site of bleeding.
- People with a wound that is not healing.
- People with poorly controlled diabetes.
- People who have a second, separate cancer that is detectable at the time of considering joining the trial.
- People experiencing symptoms caused by cancer that has spread to the brain.
- People with a significant history of neurological or mental health conditions, including seizures or dementia.
- People with a history of autoimmune disease or previous use of gamma immunoglobulin (a type of immune system treatment).
- People who would be unable to follow the study procedures.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Soo Chin Lee, National University Hospital, Singapore
Phone: +65 6908 2222
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Time to treatment failure; Progression-free survival; Duration of tumour response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.